Form 4: Inari Medical Director William Hoffman Sells Shares Under 10b5-1 Plan

Director William Hoffman of Inari Medical sold a total of 59,610 shares of common stock on December 16, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• William Hoffman, a director at Inari Medical, sold 59,610 shares of the company's common stock on December 16, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
• The transactions occurred in multiple trades at varying prices, with weighted average prices ranging from $54.33 to $56.89 per share.
• Following these transactions, Hoffman's direct ownership of Inari Medical common stock decreased to 441,233 shares.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of insider trading activity, which is neither positive nor negative in itself. The sales were pre-planned, so there is no indication of negative sentiment from the director.

Risks

• The sale of shares by a director could be perceived negatively by the market, potentially impacting the stock price.
• The use of a 10b5-1 plan suggests the director may continue to sell shares in the future.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This is a routine disclosure of insider trading activity, which is common for publicly traded companies. It does not indicate any specific trend in the medical device industry.

Comparison to Industry Standards

• Insider trading disclosures are a standard practice for all publicly listed companies, including medical device companies like Inari Medical.
• The use of a 10b5-1 trading plan is a common method for insiders to sell shares while avoiding accusations of trading on non-public information.
• Comparable companies in the medical device sector also regularly file Form 4s when insiders trade their company's stock.

Stakeholder Impact

• The sale of shares by a director could cause some concern among shareholders, although the pre-planned nature of the sales mitigates this concern.

Key Dates

Keywords

Inari Medical, William Hoffman, stock sale, Form 4, 10b5-1 plan, insider trading, NARI